Trial Profile
A Study of Intravesical Bacillus Calmette-Guerin (BCG) in Combination With ALT-803 (N-803) in Patients With Non-Muscle Invasive Bladder Cancer
Status:
Recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 17 Apr 2024
Price :
$35
*
At a glance
- Drugs Inbakicept (Primary) ; BCG
- Indications Bladder cancer; Carcinoma
- Focus Therapeutic Use
- Acronyms QUILT-2.005
- Sponsors ImmunityBio
- 11 Apr 2024 Planned End Date changed from 1 Dec 2027 to 1 Dec 2038.
- 11 Apr 2024 Planned primary completion date changed from 1 Dec 2025 to 1 Dec 2028.
- 23 Oct 2023 Results (n=9) presented in an ImmunityBio media release.